# Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

> **NCT06168084** · PHASE4 · COMPLETED · sponsor: **Yongquan Shi** · enrollment: 688 (actual)

## Conditions studied

- Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** amoxicillin
- **DRUG:** Bismuth
- **DRUG:** Esomeprazole
- **DRUG:** Tetracycline
- **DRUG:** Furazolidone

## Key facts

- **NCT ID:** NCT06168084
- **Lead sponsor:** Yongquan Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-06
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 688 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168084, "Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06168084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*